Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain.
sons [3, 4] . We previously showed that the presence of preexisting NNRTI-resistant mutants detected by population sequencing was associated with a 2.3-fold increased risk of virologic failure of first-line efavirenz-based antiretroviral therapy [5] .
Antiretroviral drug resistance testing is recommended in HIV-1-infected subjects before starting antiretroviral therapy to guide the selection of appropriate first-line regimens [2, 3] . Studies show that antiretroviral drug resistance testing is cost effective [6] and improves the virologic, immunologic, and clinical outcomes of antiretroviral therapy [5, [7] [8] [9] [10] . Current genotypic resistance assays, however, do not detect resistant viruses present in less than 15%-20% of the viral population [11, 12] . New assays, such as allele-specific real-time polymerase chain reaction (PCR), enable detection of low-abundance mutants with greater sensitivity [13] [14] [15] [16] [17] [18] [19] [20] . Through preferential amplification of different allelic variants in real-time PCR conditions, allele-specific PCR consistently detects mutants present in !0.1% of the virus population [14] .
Relative to population sequencing of plasma viruses, allelespecific PCR testing increases the detection of particular antiretroviral drug resistance mutations by 1.5-to 3-fold in different clinical settings [14, 15, 21, 22] . Whether drug-resistant mutants present at such low levels are associated with an increased risk of virologic failure of antiretroviral therapy remains unresolved. We sought to address this question with use of allele-specific PCR to detect selected NNRTI resistance mutations in pretreatment plasma specimens from subjects in a casecohort study of patients with and without virologic failure in the efavirenz arms of AIDS Clinical Trials Group (ACTG) protocol A5095 [23, 24] , a randomized trial of initial antiretroviral therapy.
METHODS

Study participants.
The ACTG A5095 study (clinicaltrials.gov identifier NCT00013520) was a randomized, controlled trial that compared the efficacy of efavirenz plus a fixed-dose combination of 2 or 3 nucleoside reverse-transcriptase inhibitors with that of a fixed-dose triple-nucleoside regimen in previously untreated HIV-1-infected subjects with plasma HIV-1 RNA levels of у400 copies/mL (Amplicor or UltraSensitive HIV-1 Monitor Assay version 1.0; Roche Molecular Systems) [23, 24] . For subjects meeting the criteria for virologic failure (2 consecutive measurements of HIV-1 RNA level у200 copies/mL, with the first measurement at least 16 weeks after study entry), population sequencing (TruGene; Siemens) of plasma viruses was performed from samples stored at the time of first virologic failure and at baseline.
Study design. A case-cohort study of ACTG A5095 was performed to determine the prevalence of NNRTI resistance and its impact on treatment outcome in the efavirenz-containing arms of this trial [5, 25] . The case-cohort sample consisted of a random sample (subcohort) stratified by and drawn from the efavirenz-containing arms of A5095, plus additional cases (virologic failures) that were not selected to be in the subcohort. The current report presents further analyses of the existing case-cohort study; the results of the relationship between mutations as detected by population sequencing and virologic failure for this cohort have been published elsewhere [5] .
To identify pretreatment minority K103N and Y181C variants, blinded pretreatment plasma samples with no NNRTI resistance detected by population sequencing were reanalyzed using allele-specific PCR. The primary outcome measure for the case-cohort study was the occurrence of virologic failure; the primary variable of interest was presence or absence of minority K103N and/or Y181C variants in the pretreatment samples. Minority variants were defined as variants detected by allele-specific PCR but not by population sequencing. Data on recent treatment adherence, defined as not missing any doses over the past 4 days [27] , were captured as part of A5095 while the subject was receiving randomized treatment at weeks 4, 12, and 24 and then every 24 weeks with use of a self-administered adherence questionnaire [26] . Given that nonadherence was associated with an increased risk of virologic failure in the main A5095 study [23] , as-treated analyses in the current study were adjusted for recent self-reported adherence.
Detection of K103N and Y181C mutants with use of allelespecific PCR. Viral RNA was extracted from 1 mL of plasma (QIAamp Viral RNA Mini Kit; Qiagen) after centrifugation at 24,000 g for 1 h at 4ЊC and was PCR amplified (Appendix, which appears only in the online version of the Journal). PCR reactions proceeded as published elsewhere [14, 19] . Clinical specimens were analyzed in the same batch with serially diluted standards (range, to standard DNA copies). The 2 7 1 ϫ 10 1 ϫ 10 percentage of HIV-1 sequences containing each mutation was calculated by dividing the number of mutant sequences by the total number of HIV-1 sequences and multiplying by 100. In addition to the sensitivity threshold for each allele-specific PCR assay, we calculated a specific detection threshold for each sample, defined as the minimum proportion of variants that could be detected on the basis of the subject's plasma HIV-1 RNA level, the volume of plasma used in the RNA extraction, the fraction of the RNA elution volume used for complementary DNA (cDNA) synthesis, and the assumed efficiencies of the RNA extraction and cDNA synthesis.
Statistical methods. Based on the random subcohort, the prevalence of baseline minority K103N and/or Y181C mutants was estimated; the prevalence of each minority variant was compared between virologic failures and nonfailures with use of the Fisher's exact test. Using an exact test for homogeneity of odds ratios, the prevalence of Y181C mutants was compared Figure 1 . Case-cohort design and subject disposition. Subjects were excluded if they had no result for both minority variants. Subjects were considered to have incomplete data if they had a result for only 1 minority variant. ASPCR, allele-specific polymerase chain reaction.
between virologic failures and nonfailures across the following subgroups: subjects with or without the K103N mutation, 4-drug or 3-drug efavirenz-based treatment, and screening HIV-1 RNA level. Summary statistics of the demographic characteristics of subjects in the random subcohort by pre-existing minority K103N and/or Y181C mutants, population resistance, or no NNRTI resistance are described, as well as for additional subjects with virologic failure. Weighted Cox proportional hazards models [29] were used to estimate the risk of virologic failure in the presence and absence of minority K103N and/or Y181C mutants at baseline among subjects without NNRTI resistance mutations by population sequencing. Unadjusted intent-to-treat and as-treated analyses showed similar results. Further as-treated analyses were adjusted for recent self-reported treatment adherence; the presence of an interaction between recent self-reported adherence and baseline NNRTI resistance was examined. Such an interaction would imply a different impact of the presence of NNRTI resistance mutations at baseline dependent on recent adherence. Subjects without allele-specific PCR results for either codon 103 or 181 were counted as missing unless otherwise specified. In a post hoc analysis, all subjects with low-level Y181C mutants at baseline and who experienced virologic failure were evaluated for the presence of resistance by population sequencing at time of virologic failure. A post hoc analysis in the random cohort compared the mean change in viral load at day 14 on study from baseline in subjects with no NNRTI resistance mutations to subjects with low-abundance Y181C variants and to subjects with bulk resistance with use of the Wilcoxon rank-sum test.
All P values and confidence intervals (CIs) presented are nominal, unadjusted for multiple comparisons.
RESULTS
Case-cohort sample. Of the 220 randomly sampled subjects, 57 (26%) were cases (virologic failure) and 163 (74%) were controls (virologic nonfailure) ( Figure 1 ). Eleven control subjects had !16 weeks of follow-up and therefore were not evaluable for the protocol-defined criteria for virologic failure; these subjects were excluded from analyses of virologic failure and were not assayed by allele-specific PCR. Reasons for premature study discontinuation included loss to follow-up (5), unable to get to clinic (4), toxicity (1), and clinical event (1). The fully evaluable random cohort sample included 195 subjects with at least 16 weeks of follow-up, of whom 12 were considered to be NNRTI resistant by population sequencing and 183 had complete allele-specific PCR results. Note, an additional 4 subjects had only allele-specific PCR data for K103N or Y181C (n p
11)
Screening HIV-1 RNA !100,000 copies/mL 67 (61) 2 (25) 25 (46) 7 (64) 8 (67) 109 (56) 66 (52) Male sex 82 (75) 8 (100) 47 (87) 9 (82) 11 (92) 157 (81) 105 ( 23 (43) 4 (36) 8 (67) 87 (45) 46 (36) Black non-Hispanic 36 (33) 2 (25) 23 (43) 4 (36) 4 (33) 69 (35) 55 (43) Hispanic (regardless of race)
24 (22) 2 (25) 7 (13) 3 (27) 0 (0) 36 (18) 23 ( 1 (2) 0 (0) 0 (0) 3 (2) 3 (2) IV drug use history Never 95 (86) 6 (75) 46 (85) 8 (73) 7 (58) 162 (83) 112 (88) Currently/previously 15 (14) 2 (25) 8 (15) 3 (27) 5 (42) 33 (17) 15 (12) HIV-1 RNA, mean log NOTE. Data are no (%) of subjects, unless otherwise indicated. The case-cohort sample consisted of a random sample (random subcohort) stratified by and drawn from the efavirenz-containing arms of the ACTG A5095 study, plus the additional cases (additional subjects with virologic failure) that were not selected to be in the subcohort. The baseline characteristics of subjects included in the random subcohort are shown for the following groups: subjects without nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance mutations detected by either population sequencing or allele-specific polymerase chain reaction (ASPCR); those without NNRTI resistance detected by population sequencing but in whom ASPCR detected only K103N mutants (K103N only), only Y181C mutants (Y181C only), or both K103N and Y181C mutants (both K103N and Y181C); subjects in whom NNRTI resistance mutations were detected by population sequencing of plasma viruses; and for all subjects included in the random subcohort (all of random subcohort). Of note, subjects with NNRTI resistance mutations detected by population sequencing were not retested using ASPCR. The Circles represent the levels at which Y181C was found among each plasma sample. Each circle corresponds to 1 subject.
but not both (2 and 2, respectively). One hundred twenty-seven additional subjects with virologic failure were added to the random subcohort (7 NNRTI resistant by population sequencing and 120 with complete allele-specific PCR results). Overall, the total case-cohort sample included 322 subjects (178 with virologic failure and 144 without virologic failure). Allele-specific PCR. The detection threshold of the allelespecific PCR was defined as 13 standard deviations above the mean of 20 repeated assays with use of the wild-type reversetranscriptase from pNL4-3 as a control target. Detection thresholds were: 0.003% for K103N (AAC), 0.001% for K103N (AAT), and 0.03% for Y181C. The difference in real-time PCR threshold cycle values between mutant and wild-type DNA equivalents was always 117 cycles. Proportion measurements were linear down to at least 0.1% in all cases.
Baseline characteristics. As reported elsewhere [5] , the prevalence of pretreatment NNRTI resistance by population sequencing in the randomly sampled subcohort was 5%; this included 6 subjects with K103N alone, 2 with K103N together with a second NNRTI resistance mutation (other than Y181C), 0 with Y181C alone, and 1 with both K103N and Y181C by population sequencing at baseline. Of the 183 subjects assayed for the presence of pre-existing low-abundance K103N and/or Y181C mutants by allele-specific PCR, variants carrying the K103N or Y181C mutations or both were detected in 8 (4.4%), 54 (29.5%), and 11 (6%) subjects, respectively. Table 1 summarizes baseline demographic characteristics of the random subcohort by presence or absence of pre-existing minority NNRTI resistance mutations and of the additional subjects with virologic failure.
Levels of low-abundance drug-resistant mutants at baseline. Among subjects in the random subcohort in whom minority NNRTI-resistant variants were detected, the median (interquartile range) levels of mutants were 0.012% (0.008%-0.116%) for K103N (AAC allele), 0.013% (0.005%-0.053%) for K103N (AAT allele), and 0.060% (0.048%-0.089%) for Y181C. Of note, the levels of Y181C and K103N mutants detected in individual samples were all !1% (Figure 2 and data not shown).
Low-abundance K103N and/or Y181C mutants and virologic failure. Pre-existing low-abundance K103N mutants were detected less often than Y181C variants. K103N minority mutants were as frequent in subjects who did not experience virologic failure as those who did in the random subcohort (Figure 3) . Of the 185 subjects in the random subcohort, 58% of those with virologic failure, compared with 29% of those without virologic failure, had low-abundance Y181C mutants at baseline ( ). The relative prevalence of Y181C mu-P p .001 tants in subjects with virologic failure, compared with subjects without virologic failure, was similar across subgroups defined by presence or absence of the K103N mutation, assignment to the 4-drug or 3-drug arm, and HIV-1 RNA level at screening (Figure 3) . In exploratory analyses, we were unable to define a threshold level of Y181C mutants that distinguished virologic failure and virologic nonfailure with high sensitivity and specificity (data not shown). A post hoc analysis of the baseline characteristics of subjects with low-abundance Y181C mutants in the randomly sampled subcohort showed no differences between those with virologic failure and those without virologic failure with regard to HIV-1 RNA levels and CD4 + T cell counts at screening or race/ethnicity (data not shown). Note, these analyses include all subjects with results for the respective minority variant.
An as-treated weighted Cox proportional hazards model adjusted for recent treatment adherence showed a significantly increased risk of virologic failure for subjects with an NNRTIresistant virus by population sequencing, compared with those with wild-type virus by population sequencing and allelespecific PCR (hazard ratio [HR], 4.00 [95% CI, 1.72-9.09]). Among subjects with wild-type HIV-1 by population sequencing, detection of low-abundance Y181C mutants by allele-specific PCR was associated with an increased risk of virologic failure (HR, 2.54 [95% CI, 1.53-4.20]). A significant association with the detection of minority K103N mutants and an increased risk of virologic failure was not detected ( ), but the P p .22 direction of the effect was similar (HR, 1.58 [95% CI, 0.76-3.28]). As seen in the study overall [23] , subjects with recent nonadherence to treatment also had an increased risk of virologic failure, compared with adherent subjects (HR, 2.30 [95% CI, 1.40-3.78]).
Further modeling suggested an interaction between baseline presence of low-abundance Y181C mutants and recent treatment adherence ( ), showing that in the presence of P p .08 Figure 3 . Prevalence of baseline minority K103N and Y181C mutants according to virologic outcome. The proportion of subjects with and without virologic failure in whom low-abundance K103N (top panel) and Y181C (bottom panel) mutations were detected at baseline among those without nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance by population sequencing in the random subcohort. The top panel includes 2 subjects with a K103N result only and the bottom panel includes 2 subjects with an Y181C result only; these subjects are excluded from all other analyses. Analyses were performed overall; for subjects with the Y181C mutation detected by allele-specific polymerase chain reaction (ASPCR) (Y181C+) or not (No Y181C); for subjects with the K103N mutation detected by ASPCR (K103N+) or not (No K103N); for those receiving abacavir (ABC), zidovudine (ZDV), lamivudine (3TC), and efavirenz (EFV) or those receiving ZDV, 3TC, and EFV; and for subjects with human immunodeficiency virus type 1 levels (VL) at screening у100,000 or !100,000 copies/mL. The prevalence of low-abundance K103N mutants among subjects with virologic failure and those without virologic failure was not significantly different overall (P value not shown). P value for difference in prevalence of low-abundant Y181C mutants among those with virologic failure and those without virologic failure overall is shown. P interaction values are based on exact test for homogeneity of odds ratios across subgroups. P values are nominal and unadjusted for multiple comparisons. * ; ** ; *** .
recent nonadherence, the effect of minority Y181C was diminished ( Figure 4) . Among adherent subjects, the presence of minority Y181C by allele-specific PCR was associated with an increased risk of virologic failure, compared with the absence of Y181C by both population sequencing and allele-specific PCR testing (HR, ). Similar results were P p .46 obtained when repeating this analysis with use of the presence of any minority variant (either K103N or Y181C) (data not shown).
NNRTI resistance mutations at virologic failure. Sixty-five subjects with low-abundance Y181C mutants at baseline ex- perienced virologic failure and had a viral genotype (by population sequencing) available at the time of virologic failure. No resistance mutations were detected in 27 (41.5%), K103N was detected in 25 (38.5%), Y181C was detected in 5 (7.7%), and K101E was detected in 4 (6.2%); 2 of these 4 (3.1%) also had the K103N mutation (Table 2) .
Low-abundance K103N and/or Y181C mutants and viral dynamics. Following these observations, we chose to examine whether low-abundance Y181C mutants impacted initial decreases (to day 14) in HIV-1 RNA level on treatment initiation. To avoid bias from oversampling of subjects with virologic failure, these analyses were limited to the random cohort. Among subjects in the random cohort with available sequencing and day 14 viral load data, the mean change in viral load at day 14 on study from baseline was not significantly different between subjects with low-abundance Y181C and subjects with no NNRTI resistance mutations ( ); a significantly P p .97 smaller mean change in viral load at day 14 from baseline was detected in subjects with bulk resistance (mean change, Ϫ1.53 log 10 copies/mL), compared with subjects with no NNRTI resistance mutations (mean change, Ϫ2.06 log 10 copies/mL) (difference, 0.52 log 10 copies/mL [95% CI, 0.13-0.91 log 10 copies/ mL;
). P p .01
DISCUSSION
Detection of pre-existing minority Y181C mutants encoding NNRTI resistance was associated with a 13-fold increased risk of virological failure of initial antiretroviral therapy with efavirenz-based regimens in antiretroviral therapy-naive HIV-1-infected subjects in the presence of perfect treatment adherence. The increased risk persisted across subjects with diverse baseline characteristics, including those with plasma HIV-1 RNA levels у100,000 or !100,000 copies/mL; the risk magnitude was considerable and clinically relevant. Importantly, the impact of the presence of low-abundance Y181C mutants on the risk of virologic failure was diminished among nonadherent subjects. These findings confirm the importance of pre-existing resistant viruses present as minority members of the viral quasispecies in determining the virologic outcome of antiretroviral therapy, particularly in the case of drugs with a low genetic barrier to resistance. They also underscore the clinical need for improving the sensitivity of genotypic drug resistance assays.
Mutations Y181C and K103N were chosen for the allele-specific PCR analysis because they are the most frequent NNRTI resistance mutations found after virologic failure of nevirapine and efavirenz. Minority Y181C and K103N mutants were detected by allele-specific PCR in nearly 40% of subjects with wild-type virus by standard genotypic testing. This prevalence represented an almost 9-fold increase in the detection of primary NNRTI resistance when the results of allele-specific PCR plus population sequencing (44%) were compared with population sequencing alone (5%).
In the current study, we did not detect an association between the presence of low-abundance K103N mutants and increased risk of virologic failure. This observation contrasts with previous studies, including our own finding in the same study population of a significantly increased risk of virologic failure when K103N was detected by population sequencing. However, this discrepancy may be attributable to the relatively small number of subjects with low-abundance K103N mutants identified by allele-specific PCR.
It is noteworthy that all of the mutants identified by allelespecific PCR in our study were present at levels !1%. Although these low levels could represent underestimation because of polymorphisms at the primer binding sites in the target sequences, it would be surprising if this were the case in every subject tested. A more likely explanation is that Y181C and K103N mutants present at higher levels had already been identified by population sequencing, because samples from those subjects were not retested by allele-specific PCR. This interpretation is consistent with data generated by ultradeep pyrosequencing [22] , which found that NNRTI-resistant mutants were either present at relatively high levels (120%, and thus detectable by population sequencing) or at low levels (generally less than 1%-5%). These findings suggest that ultrasensitive resistance assays should have sufficient sensitivity to detect variants present at less than 1%-5% of the plasma virus population.
Our study extends the findings of 2 previous studies. A retrospective case-control analysis from the United States Centers for Diseases Control and Prevention (CDC) applied a modified allele-specific PCR technique to baseline samples drawn from 2 clinical trials of efavirenz-containing first-line regimens [33] . Presence of minority mutations at reverse transcriptase codons 103, 181, or 184 was associated with 11-fold increased odds of virologic failure, but these mutations were detected in only a small number of subjects (7 of 95 with virologic failure and 2 of 221 with virologic suppression). The contribution of each individual mutation to the risk of virologic failure could not be assessed.
Analysis of baseline resistance by ultradeep pyrosequencing in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study, which compared initial antiretroviral therapy strategies including an NNRTI, protease inhibitor, or both [34] , found that pre-existing minority NNRTI-resistant variants more than tripled the hazard of virological failure in antiretroviral therapynaive subjects starting NNRTI-based therapy [22] . Similarly, all 4 subjects in the protease inhibitor arm in whom protease inhibitor-resistant minority variants were detected experienced virologic failure, but the numbers were too small to show a statistically significant increase in the risk of virologic failure.
The clinical application of allele-specific PCR or any other resistance assay requires a precise refinement of thresholds that identify subjects at greatest risk of virologic failure. We were unable to define a threshold level of mutants that distinguished between subjects who experienced virologic failure and subjects who did not experience virologic failure with high sensitivity and specificity. Although subjects with minority Y181C variants were at greater risk of virologic failure, 70% of these subjects nevertheless achieved long-term viral suppression when receiving their initial efavirenz-based regimen. In post hoc exploratory analyses, we were unable to identify factors that explained this difference. The high sensitivity of allele-specific PCR may capture natural fluctuations within the quasispecies over time that are not necessarily clinically significant. Conversely, the other 2 studies addressing the clinical relevance of minority variants used higher thresholds for detecting minor variants. Because the modified allele-specific PCR method used in the CDC study [33] was designed to detect mutant viruses above the natural quasispecies frequency of each mutation, the actual threshold for detecting the K103N and Y181C mutants was 0.9% and 1.0%, respectively, which is at least 2 orders of magnitude higher than with our approach. Indeed, the clonal frequencies of the resistant variants in the CDC study ranged between 0.6% and 12.5%, suggesting a lower sensitivity of the allele-specific PCR method used by the CDC, relative to ours. Similarly, because of the error rate of pyrosequencing, the cut off for detecting minority variants in the FIRST study [22] was established at 1%. Though the CDC and the FIRST studies could have missed clinically relevant minority mutants, a number of minority mutants detected in our study did not contribute to virologic failure during the study period. Determining the optimum threshold to maximize sensitivity and specificity requires analysis of a larger number of samples than has been available in studies performed to date.
Although the presence of pre-existing low-abundance Y181C mutants was associated with a greater risk of virologic failure, other efavirenz resistance mutations were more commonly found at the time of virologic failure. Similar results were obtained in the FIRST study [22] . It is possible that presence of the Y181C mutants was a marker for presence of other, undetected NNRTI mutants that emerged under efavirenz selection. Alternatively, the low-level efavirenz resistance conferred by Y181C could have allowed ongoing virus replication that led, in turn, to the later accumulation of other NNRTI resistance mutations, such as K103N or G190S. Persistence of Y181C might have been selected against by the coadministration of zidovudine, because Y181C increases HIV-1 susceptibility to that drug [30] [31] [32] . Because we did not attempt to detect minority nucleotide reverse-transcriptase inhibitor-resistant variants at baseline, we cannot fully rule out that pre-existence of some of such variants (eg, M184V) could have influenced the risk of virologic failure.
In conclusion, low-abundance NNRTI-resistant variants significantly increased the risk of virologic failure of initial antiretroviral therapy with efavirenz among adherent subjects; these minority mutants did not add to the risk of virologic failure associated with nonadherence. More-sensitive resistance assays could improve the clinical management of HIV-infected subjects. The clinical application of such assays, however, will require further technical developments, a better understanding of the role of low-abundance resistant variants in different clinical scenarios, and refinement of assay thresholds that identify patients at greatest risk of virologic failure.
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